Krilogy Financial’s Insys Therapeutics, Inc. INSY Stock Holding History

Krilogy Financial’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,403	Closed	-$14K	–	806
2018 Q3	$14K	Buy	+1,403	New	+$11.2K	﹤0.01%	490
2018 Q2	–	Sell	-1,403	Closed	-$8K	–	721
2018 Q1	$8K	Hold	1,403	–	–	﹤0.01%	557
2017 Q4	$13K	Hold	1,403	–	–	﹤0.01%	498
2017 Q3	$12K	Buy	1,403 +485	+53%	+$5K	﹤0.01%	564
2017 Q2	$12K	Buy	+918	New	+$10.9K	﹤0.01%	519

Other funds holding INSY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Krilogy Financial's INSY Position: Q4 2018 in Review

Krilogy Financial sold out of Insys Therapeutics, Inc. (INSY) in Q4 2018, closing a stake of 1,403 shares — an estimated $14K sold.

Krilogy Financial first reported a position in INSY in Q2 2017 and held it in 5 quarters. The position peaked at $14K in Q3 2018. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2018.

Krilogy Financial reported no remaining Insys Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
Krilogy Financial sold 1,403 Insys Therapeutics, Inc. shares in Q4 2018, an estimated $14K.
Krilogy Financial first reported a position in Insys Therapeutics, Inc. in Q2 2017 and held it in 5 quarters.
Krilogy Financial's Insys Therapeutics, Inc. position peaked at $14K in Q3 2018.
113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.